Latest news for Morgan Stanley (NYSE:MSpA) Stock

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 30% of its total revenue is from outside the Americas. The company had over $5 trillion of client assets as well as around 80,000 employees at the end of 2023.

Morgan Stanley Dep Shs repstg 1/1000 Pfd Ser A

Morgan Stanley

Scotiabank analyst Paul Cheng maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Sector Perform and lowers the price target from $150 to $140.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on EOG Resources, Lowers Price Target to $140

Truist Securities analyst Joseph Civello upgraded Nike, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) to Buy from Hold and raised the <a target="_blank" href="https://www.benzinga.com/quote/NKE/analyst-ratings" rel="noreferrer noopener">price target to $97 from $83</a>.
The analyst writes that while he still sees the turnaround process as lengthy and uncertain, he is more optimistic about the stock as investor expectations now seem more realistic.
In particular, the analyst attributes Nike&#8217;s recent struggles to its heavy focus on DTC growth since 2020, which has stifled innovation and caused customer fatigue with key products, making its current franchise management strategy necessary.
Exiting retail partnerships also resulted in share losses to competitors like ONON and HOKA, which will be difficult to regain, adds the analyst.
With experienced company leadership back in charge, the analyst believes that they are steering in the right direction.
Civello sees the rehiring of 30-year veteran Tom Peddie and the appointment of incoming CEO Elliot Hill, with his strong experience in marketplace and marketing, as<a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39683071/whats-going-on-with-sneaker-giant-nikes-shares-today" rel="noreferrer noopener"> key steps in driving the turnaround</a>.
Although a full recovery is a long-term goal, near-term wins—like increased marketing investment, improved wholesale relationships, and promoting ambassador Caitlin Clark should help demonstrate to investors that better times are ahead, adds the analyst.
Civello maintained EPS estimates at $2.75 for 2025 and $3.10 for 2026.
This month, the athletic footwear and apparel&nbsp;company reported first-quarter revenue of $11.59 billion, missing analyst&nbsp;estimates&nbsp;of $11.65 billion and EPS of 70 cents per share, beating analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41129610/nike-q1-earnings-revenue-miss-eps-beat-teams-energized-amid-ceo-transition-a-comeback-at-this-scale" rel="noreferrer noopener">estimates of 52 cents per share</a>.
Investors can gain exposure to the stock via&nbsp;First Trust Dow 30 Equal Weight ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDOW#NYSE">EDOW</a>) and VanEck ETF Trust VanEck Morningstar Wide Moat Value ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MVAL#BATS">MVAL</a>).
Price Action: NKE shares are down 0.27% at $82.23 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254904/nikes-forward-march-hits-speed-bumps-analyst-identifies-red-flags-in-sec-filing" target="_blank" rel="noreferrer noopener">Nike&#8217;s Forward March Hits Speed Bumps: Analyst Identifies Red Flags In SEC Filing</a></li>
</ul>

Analyst Color

Equities

Large Cap

Upgrades

Trading Ideas

EDOW

MVAL

Nike Upgraded: Analyst Optimistic Despite Lengthy Process And Competitive Challenges

Scotiabank analyst Paul Cheng maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Sector Outperform and lowers the price target from $245 to $225.

FANG

Scotiabank Maintains Sector Outperform on Diamondback Energy, Lowers Price Target to $225

United States Senator Elizabeth Warren wrote a letter to the Federal Trade Commission&#8217;s chair, Lina Khan, urging to investigate Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) proposed $16.5 billion acquisition of contract development and manufacturing organization Catalent Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>) thoroughly, amid growing concerns about <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36931734/ozempic-maker-strikes-11b-deal-with-catalent-as-it-rushes-to-meet-massive-weight-loss-drug-demand" rel="noreferrer noopener">potential antitrust violations</a>.
Critics argue that this merger could increase Novo Nordisk&#8217;s control over producing vital GLP-1 receptor agonists, drugs used to treat diabetes and obesity. This could potentially drive up prices and limit competition.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41184148/novo-nordiskastrazenecas-manufacturing-partner-thermo-fisher-questioned-over-manufacturing-lapses" rel="noreferrer noopener">Novo Nordisk/AstraZeneca&#8217;s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses</a>.
Novo Nordisk already has a dominant 55% share of the booming GLP-1 market due to the success of its blockbuster drugs, Ozempic and Wegovy.
Catalent plays a key role in filling and packaging Novo Nordisk&#8217;s GLP-1 products, but it also works with Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk&#8217;s main competitor in the GLP-1 market, primarily through its tirzepatide-based drugs, Mounjaro and Zepbound.
The concern is that if Novo Nordisk acquires Catalent, it could gain unprecedented access to Eli Lilly&#8217;s production capacity, potentially allowing it to prioritize its drugs over its competitors.
The letter <a target="_blank" href="https://www.warren.senate.gov/imo/media/doc/catalent1.pdf" rel="noreferrer noopener">highlights</a> that Novo Nordisk has faced scrutiny from the FTC. Earlier this year, the FTC warned Novo Nordisk for improperly listing patents related to its diabetes drugs in the FDA&#8217;s Orange Book.
This behavior, combined with the company&#8217;s current plans to acquire Catalent, raises concerns about Novo Nordisk&#8217;s ability to further hinder competition.
Over recent decades, the consolidation of the U.S. pharmaceutical industry has led to fewer dominant firms and higher drug prices. From 1995 to 2015, major pharmaceutical companies dropped from 60 to just 10, as large corporations increasingly controlled healthcare services, from insurance to pharmacies.
Novo Nordisk&#8217;s proposed acquisition of Catalent is considered part of this broader trend of vertical integration.
While Novo Nordisk claims it prioritizes patient access to diabetes medications, critics argue its actions suggest otherwise. The company recently discontinued Levemir, a long-acting insulin, the only option approved for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39801282/senate-to-review-novo-nordisks-levemir-insulin-discontinuation" rel="noreferrer noopener">use during pregnancy</a>.
Although Novo Nordisk cited unfavorable formulary placement as the reason, the decision is seen as a way to reallocate production resources to its more profitable GLP-1 drugs.
Price Action: At last check Thursday, NVO stock was up 0.46% at $117.54, and CTLT stock was down 0.53% at $60.64.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41274383/why-is-japanese-anime-production-company-bloomz-stock-jumping-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Japanese Anime Production Company BloomZ Stock Jumping On Thursday?</a></li>
</ul>

Biotech

Government

Health Care

Legal

General

CTLT

FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears

Scotiabank analyst Paul Cheng maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Sector Outperform and lowers the price target from $60 to $48.

Scotiabank Maintains Sector Outperform on Devon Energy, Lowers Price Target to $48

Scotiabank analyst Paul Cheng maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Sector Outperform and lowers the price target from $35 to $32.

CTRA

Scotiabank Maintains Sector Outperform on Coterra Energy, Lowers Price Target to $32

Celsius Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) shares are trading higher Thursday, bouncing back from steep losses in recent quarters. Here&#8217;s a look at <a href="https://www.benzinga.com/news/24/10/41261919/what-happened-with-celsius-holdings-stock-today">what&#8217;s going on</a>.
What To Know: Celsius shares are moving swiftly higher Thursday on increased attention from retail traders. The stock was trending across several social sites at last check. It was the top trending name on Stocktwits and was among the most mentioned stocks on Reddit&#8217;s r/WallStreetBets over the past 24 hours. 
Traders appear to be pointing to a confluence of bullish indicators including support levels dating back to 2022 and an oversold relative strength index (RSI). Traders are also highlighting notable short interest as potential fuel for a sharp bounce. 11.79% of Celsius&#8217; float is currently sold short, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
A spike in options volume suggests traders are betting on a continued bounce. Thursday&#8217;s options volume was around 252,919 at the time of writing versus Celsius&#8217; 30-day average options volume of 57,335, per Barchart <a href="https://www.barchart.com/stocks/quotes/CELH/overview">data</a>.
See Also: <a href="https://www.benzinga.com/trading-ideas/24/10/41274987/how-to-watch-tesla-robotaxi-day-live-elon-musks-autonomous-vehicle-event-is-here">How To Watch Tesla Robotaxi Day Live: Elon Musk&#8217;s Autonomous Vehicle Event Is Here</a>
Celsius shares hit new 52-week lows this week. The stock has been under pressure as the company has battled market share declines on the back of softer demand. Celsius was experiencing sales growth of more than 50% at the start of the year, but growth has reportedly <a href="https://www.benzinga.com/news/24/10/41216891/celsius-holdings-stock-hit-52-week-lows-on-monday-whats-going-on">fallen to around 10%</a> in the current quarter.
The selloff in Celsius shares accelerated last month after the company said distribution partner PepsiCo was scaling back orders by about $100 million to right-size its inventory.
Following Celsius&#8217; second-quarter earnings in August, several analysts lowered price targets on the stock. Last week, BofA Securities analyst Jonathan Keypour <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40264027/celsius-holdings-downgraded-analyst-cautions-weak-consumer-environment-no-meaningfu">downgraded Celsius</a> citing a sharp sequential decline in sales. The analyst lowered earnings estimates moving forward and noted that he doesn&#8217;t expect a meaningful recovery until mid-2025.
Celsius is due to report quarterly results at the beginning of November. Analysts currently expect the company to report earnings of 5 cents per share and revenue of $273.751 million, according to<a href="http://pro.benzinga.com"> Benzinga Pro</a>.
CELH Price Action: <a href="http://benzinga.com/quote/celh">Celsius shares</a> were up 12.8% at $34.40 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

CELH

Celsius Holdings Stock Is Surging Thursday: What's Going On?

Scotiabank analyst Paul Cheng maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Sector Perform and lowers the price target from $120 to $115.

Scotiabank Maintains Sector Perform on ConocoPhillips, Lowers Price Target to $115

Scotiabank analyst Paul Cheng maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Sector Outperform and lowers the price target from $180 to $163.

Scotiabank Maintains Sector Outperform on Chevron, Lowers Price Target to $163

Scotiabank analyst Paul Cheng maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Sector Perform and lowers the price target from $30 to $27.

Scotiabank Maintains Sector Perform on APA, Lowers Price Target to $27

<a href="https://www.federalreserve.gov/newsevents/pressreleases/enforcement20241010a.htm" title="https://www.federalreserve.gov/newsevents/pressreleases/enforcement20241010a.htm">https://www.federalreserve.gov/newsevents/pressreleases/enforcement20241010a.htm</a>
&nbsp;
The Federal Reserve Board on Thursday fined Toronto-Dominion Bank $123.5 million for violations related to anti-money laundering laws. The Board is also requiring TD to implement enhanced measures to comply with anti-money laundering laws and to correct its risk management deficiencies.
TD failed to conduct adequate risk management and oversight of its retail banking operations in the United States, resulting in a U.S. subsidiary being used to launder hundreds of millions of dollars in illicit proceeds. The Board&#39;s action will help ensure that TD operates in compliance with all U.S. laws and regulations.
The Board is requiring TD to:
<ul>
<li>Establish a new office in the United States dedicated to remediating the deficiencies identified in the order;</li>
<li>Relocate to the United States the parts of its anti-money laundering compliance program that are responsible for complying with U.S. law. This program will be subject to oversight by U.S. regulators;</li>
<li>Certify that sufficient resources and attention are allocated to correcting the firm&#39;s anti-money laundering deficiencies prior to issuing any dividends or capital distributions; and</li>
<li>Undertake a thorough and independent review of the firm&#39;s board of directors and management to ensure adequate oversight of the U.S. operations.</li>
</ul>
Canada&#39;s Office of the Superintendent of Financial Institutions, the home country supervisor of TD, can act in the implementation of these requirements as permitted by its legal authority.
This action is being taken in conjunction with criminal and regulatory actions that are being taken by the U.S. Department of Justice, the U.S. Attorney&#39;s Office for the District of New Jersey, the Department of the Treasury&#39;s Financial Crimes Enforcement Network, and the Office of the Comptroller of the Currency. The penalties announced by the agencies total approximately $3.09 billion. The bank is also pleading guilty to criminal charges brought by law enforcement authorities.

TD Bank Pleads Guilty To Violations Of Bank Secrecy Act And Money Laundering, Will Pay $3B In Fines; US Regulators Impose Asset Cap And Restrict New Branches Or Services Until Compliance Issues Are Resolved; DOJ And OCC Cite Long-Term, Systemic Deficiencies In Anti-Money Laundering Efforts

B of A Securities analyst Joshua Shanker maintains Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) with a Underperform and raises the price target from $275 to $282.

B of A Securities Maintains Underperform on Chubb, Raises Price Target to $282

NVDA

CNBC Halftime Report Final Trades: NVIDIA, Samsara, SPDR Select Sector Fund - Health Care

B of A Securities analyst Joshua Shanker maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Buy and raises the price target from $81 to $96.

B of A Securities Maintains Buy on Axis Capital Holdings, Raises Price Target to $96

Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) has outperformed the market over the past 10 years by 58.48% on an annualized basis producing an average annual return of 70.42%. Currently, Celsius Holdings has a market capitalization of $8.03 billion. 
Buying $1000 In CELH: If an investor had bought $1000 of CELH stock 10 years ago, it would be worth $187,889.25 today based on a price of $34.44 for CELH at the time of writing.
<h3>Celsius Holdings's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728579690_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $190 Thousand Today

Ratings for Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.8, a high estimate of $53.00, and a low estimate of $5.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 34.25%. 
<img src="https://www.benzinga.com/files/images/story/2024/1728579689_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Virgin Galactic Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noah Poponak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Kristine Liwag</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$5.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Noah Poponak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Adjusts</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Virgin Galactic Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Virgin Galactic Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Virgin Galactic Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Virgin Galactic Hldgs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPCE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Virgin Galactic Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Virgin Galactic Hldgs's Background</h2>
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals &amp; researchers, and it also manufactures advanced air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
<h3>Financial Milestones: Virgin Galactic Hldgs's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Virgin Galactic Hldgs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 125.55%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2222.16%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Virgin Galactic Hldgs's ROE excels beyond industry benchmarks, reaching -23.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.76%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.06, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPCE

Deep Dive Into Virgin Galactic Hldgs Stock: Analyst Perspectives (5 Ratings)

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) has outperformed the market over the past 20 years by 1.05% on an annualized basis producing an average annual return of 9.65%. Currently, Honeywell Intl has a market capitalization of $138.37 billion. 
Buying $1000 In HON: If an investor had bought $1000 of HON stock 20 years ago, it would be worth $6,456.51 today based on a price of $212.98 for HON at the time of writing.
<h3>Honeywell Intl's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728579685_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,500 Today

Whales with a lot of money to spend have taken a noticeably bullish stance on Schlumberger.
Looking at options history for Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 12% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $330,325 and 4, calls, for a total amount of $191,815.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $55.0 for Schlumberger over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Schlumberger's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Schlumberger's significant trades, within a strike price range of $40.0 to $55.0, over the past month.
<h3>Schlumberger Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728579684_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$11.4</td>
<td>$11.35</td>
<td>$11.4</td>
<td>$55.00</td>
<td>$132.2K</td>
<td>227</td>
<td>163</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.52</td>
<td>$0.51</td>
<td>$0.51</td>
<td>$43.50</td>
<td>$81.6K</td>
<td>755</td>
<td>1.5K</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.5</td>
<td>$0.44</td>
<td>$0.44</td>
<td>$40.00</td>
<td>$62.8K</td>
<td>18.3K</td>
<td>1.4K</td>
</tr>
<tr>
<td>SLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.55</td>
<td>$42.50</td>
<td>$60.9K</td>
<td>2.5K</td>
<td>205</td>
</tr>
<tr>
<td>SLB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.05</td>
<td>$2.96</td>
<td>$2.97</td>
<td>$45.00</td>
<td>$59.3K</td>
<td>9.0K</td>
<td>325</td>
</tr>
</tbody>
</table>

<h3>About Schlumberger</h3>
SLB is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
After a thorough review of the options trading surrounding Schlumberger, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Schlumberger Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,810,654, with SLB's price up by 1.45%, positioned at $44.85.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Schlumberger</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $59.9.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from DBS Bank has revised its rating downward to Buy, adjusting the price target to $64. 
&#x2A; An analyst from UBS persists with their Buy rating on Schlumberger, maintaining a target price of $57. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Schlumberger, targeting a price of $49. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Schlumberger, which currently sits at a price target of $60. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $69. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Schlumberger options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Check Out What Whales Are Doing With SLB

Analysts' ratings for Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $208.08, a high estimate of $250.00, and a low estimate of $160.00. A 7.89% drop is evident in the current average compared to the previous average price target of $225.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1728579682_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Atlassian among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$175.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$177.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$225.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Atlassian. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Atlassian compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Atlassian's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Atlassian's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Atlassian analyst ratings.</a>
<h2>Delving into Atlassian's Background</h2>
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
<h3>Atlassian's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Atlassian's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 20.5%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Atlassian's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Atlassian's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.17%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Atlassian's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Atlassian's debt-to-equity ratio stands notably higher than the industry average, reaching 1.21. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TEAM

Key Takeaways From Atlassian Analyst Ratings

Whales with a lot of money to spend have taken a noticeably bearish stance on Albemarle.
Looking at options history for Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $224,452 and 3, calls, for a total amount of $76,385.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $110.0 for Albemarle, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Albemarle stands at 938.5, with a total volume reaching 155.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Albemarle, situated within the strike price corridor from $55.0 to $110.0, throughout the last 30 days.
<h3>Albemarle Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728579679_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$14.65</td>
<td>$14.45</td>
<td>$14.65</td>
<td>$110.00</td>
<td>$58.6K</td>
<td>420</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.05</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$90.00</td>
<td>$48.9K</td>
<td>894</td>
<td style="text-align: right;">98</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.85</td>
<td>$4.8</td>
<td>$4.85</td>
<td>$90.00</td>
<td>$47.5K</td>
<td>894</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ALB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.65</td>
<td>$14.2</td>
<td>$14.65</td>
<td>$110.00</td>
<td>$43.9K</td>
<td>2.9K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ALB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$51.3</td>
<td>$50.3</td>
<td>$51.3</td>
<td>$55.00</td>
<td>$25.6K</td>
<td>34</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>

<h3>About Albemarle</h3>
Albemarle is one of the world's largest lithium producers. In the lithium industry, the majority of demand comes from batteries, where lithium is used as the energy storage material, particularly in electric vehicles. Albemarle is a fully integrated lithium producer. Its upstream resources include salt brine deposits in Chile and the US and two hard rock mines in Australia, both of which are joint ventures. The company operates lithium refining plants in Chile, the US, Australia, and China. Albemarle is a global leader in the production of bromine, used in flame retardants. It is also a major producer of oil refining catalysts.
<h3>Albemarle's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 864,735, the ALB's price is up by 1.09%, now at $103.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Expert Opinions on Albemarle</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $110.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Albemarle with a target price of $110. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Albemarle options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Morgan Stanley

News

Latest news for Morgan Stanley (NYSE:MSpA) Stock